Trial's first and second cohorts maintaining signs of potential efficacy out to 24 weeksData from  the second cohort showed improvements in eosinophil counts and histological scores out to 12 weeks suggesting a dose response over the first cohortData from the trial's third cohort suggest improvements in patient-reported symptoms and histological outcomes at 12 weeksEP-104GI showed an encouraging safety profile in all three cohortsVICTORIA, BC, May 21, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced ...

LISHUI, China, May 21, 2024 /PRNewswire/ -- Tantech Holdings Ltd (NASDAQ: TANH) ("Tantech" or the "Company") announced today that it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 20, 2024 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of the Company's common shares on ...

SHANGHAI, May 20, 2024 /PRNewswire/ -- MultiMetaVerse Holdings Limited ("MMV" or the "Company"), a leading animation and entertainment company for young consumers in China, announced today that it has entered into a non-binding term sheet (the "Term Sheet") for the acquisition (the "Proposed Transaction") of 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries (collectively "Bowong AI") by the issuance of the Company's Class A ordinary shares to the shareholders of Bowong AI as consideration (the "Consideration Shares"), the amount of which will be determined  based on further due diligence and negotiation. The Consideration Shares shall be subject to ...

Forward Air Corporation (NASDAQ: FWRD) (“Forward” or the “Company”) today announced the appointment of Jamie G. Pierson as interim Chief Financial Officer effective May 20, 2024. Mr. Pierson succeeds Rebecca Garbrick, who is departing the Company. Ms. Garbrick will remain with the Company to assist with the transition.